- Home
- VNDA vs EVMN Comparison
VNDA vs EVMN Comparison
Compare VNDA & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNDA | EVMN |
|---|---|---|
| Founded | 2002 | 2020 |
| Country | United States | United States |
| Employees | N/A | 48 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.4M | 405.2M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | VNDA | EVMN |
|---|---|---|
| Price | $4.99 | $14.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $14.90 | ★ $43.88 |
| AVG Volume (30 Days) | ★ 943.3K | 571.0K |
| Earning Date | 05-06-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $216,105,000.00 | N/A |
| Revenue This Year | $21.35 | N/A |
| Revenue Next Year | $37.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.72 | N/A |
| 52 Week Low | $4.17 | $10.47 |
| 52 Week High | $9.91 | $33.20 |
Technical Indicators
Market Signals| Indicator | VNDA | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 37.50 | 49.69 |
| Support Level | $4.94 | $12.07 |
| Resistance Level | $5.58 | $21.21 |
| Average True Range (ATR) | 0.26 | 0.82 |
| MACD | 0.00 | 0.55 |
| Stochastic Oscillator | 61.66 | 94.48 |
Price Performance
Historical ComparisonAbout VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.